Soliqua 100/33 (Sanofi-Aventis U.S. LLC)
Welcome to the PulseAid listing for the Soliqua 100/33 drug offered from Sanofi-Aventis U.S. LLC. This Insulin [Chemical/Ingredient],Insulin Analog [EPC],GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [Chemical/Ingredient],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Sanofi-Aventis U.S. LLC |
| NON-PROPRIETARY NAME: | insulin glargine and lixisenatide |
| SUBSTANCE NAME: | INSULIN GLARGINE; LIXISENATIDE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Insulin [Chemical/Ingredient],Insulin Analog [EPC],GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [Chemical/Ingredient],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
| ROUTE: | SUBCUTANEOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2016-11-21 |
| END MARKETING DATE: | 0000-00-00 |
Soliqua 100/33 HUMAN PRESCRIPTION DRUG Details:
| Item Description | Soliqua 100/33 from Sanofi-Aventis U.S. LLC |
| LABELER NAME: | Sanofi-Aventis U.S. LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100; 33(U/mL; ug/mL) |
| START MARKETING DATE: | 2016-11-21 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0024-5761_e4e75cc9-4d65-46b6-9e7a-d6c433c580e9 |
| PRODUCT NDC: | 0024-5761 |
| APPLICATION NUMBER: | NDA208673 |
Other INSULIN GLARGINE; LIXISENATIDE Pharmaceutical Manufacturers / Labelers:
